LENZ Therapeutics, Inc. (NASDAQ: LENZ) is reducing its workforce by approximately 75% to around 40 full-time employees as it redirects spending toward consumer marketing for VIZZ, its newly commercialised prescription eye drop for presbyopia. President and Chief Executive Officer Eef Schimmelpennink will also step down from the top role on December 1, with Chief Financial Officer Dan Chevallard becoming interim President and CEO. The restructuring is unusually aggressive for a company that reported a 50% sequential increase in third-quarter VIZZ product sales to $2.6 million and held $197.3 million of cash, equivalents and marketable securities at September 30. LENZ is effectively concluding that its initial launch organisation costs too much relative to the revenue it currently produces, even though early prescriptions and refill behaviour suggest the product itself is gaining traction.
Why is LENZ Therapeutics removing 75% of its employees when VIZZ sales are increasing?
VIZZ generated more than 38,000 paid prescriptions during the third quarter, up approximately 51% from the second quarter, while product sales increased roughly 50% to $2.6 million. More than 15,000 unique eye-care professionals had prescribed VIZZ since launch and over 75% of them had prescribed the medicine more than once.
Telehealth has also started contributing materially. LENZ launched an integrated telehealth prescribing option in July, and the channel generated more than half of the incremental prescriptions recorded during the third quarter. That suggests consumer-access initiatives can expand adoption without relying entirely on a large traditional field organisation.
The expense structure is the problem. Selling, general and administrative expenditure reached $35.8 million during Q3, compared with only $2.6 million of product sales. Nine-month SG&A spending reached $120.2 million, more than double the $51.5 million recorded during the comparable 2025 period as LENZ invested in sales staff, advertising and launch infrastructure.
A commercial-stage pharmaceutical company can justify heavy launch spending if revenue scales quickly enough to absorb it. LENZ has concluded that its existing organisational model would consume too much capital while waiting for VIZZ sales to mature, making a radical reduction financially rational even while the underlying product grows.
How much will the workforce restructuring change LENZ Therapeutics’ cost base?
LENZ expects to reduce projected 2027 annual operating expenses by more than 50%. Management is targeting approximately $70 million to $75 million of operating expenditure next year, excluding stock-based compensation.
The restructuring itself is expected to cost approximately $5 million, principally through severance and related termination benefits. Substantially all activities are expected to be completed during the fourth quarter.
Reducing the organisation to around 40 employees leaves a significantly smaller fixed-cost structure while preserving capabilities management believes are necessary for commercialisation. The strategy places greater emphasis on consumer advertising, telehealth and other activities that can be measured directly against prescription growth.
LENZ has substantial liquidity relative to its market capitalisation. Cash, equivalents and marketable securities totalled $197.3 million at September 30, while total liabilities were only $17.8 million. The balance sheet therefore gives management time, but investors are clearly demanding evidence that the cash can be converted into product value rather than simply funding a large commercial infrastructure.
Why is the CEO changing at the same time as the organisation shrinks to about 40 employees?
Schimmelpennink will transition out of the President and CEO role on December 1 after almost six years leading LENZ. The company says his decision was not the result of a dispute or disagreement, and he is expected to remain temporarily as a strategic adviser to support the transition.
Chevallard’s promotion from CFO to interim CEO fits the immediate priorities of the restructuring. LENZ is shifting from expensive launch buildout toward capital efficiency, making financial discipline particularly important over the next several quarters.
A permanent CEO search could eventually result in a leader with deeper consumer-commercial experience, although LENZ has not announced such an outcome. For now, Chevallard inherits a simplified mandate: increase awareness and adoption of VIZZ without rebuilding the cost structure management has just dismantled.
The leadership change also creates a cleaner accountability point. The next management team will not be judged primarily on achieving FDA approval because that milestone is already complete. It will be judged on whether an approved product can generate enough recurring prescriptions to justify the cash already invested in bringing it to market.
Why has the market remained so sceptical despite VIZZ reaching commercial launch?
LENZ shares closed at $3.05 on October 30, down 12.6% for the session and approximately 90% below the stock’s 52-week high of $32.13. Trading volume was well above recent averages, indicating elevated investor attention following the restructuring and earnings update.
The valuation reflects the gap between early commercial momentum and the scale of current revenue. Third-quarter net product sales of $2.6 million remain small compared with quarterly SG&A expenditure exceeding $35 million.
The company’s cash balance is significantly larger than its market capitalisation, but that observation does not by itself make the stock undervalued. Cash belongs to shareholders only to the extent that management can preserve or deploy it productively; continuing operating losses can consume that balance quickly.
The restructuring is therefore an attempt to change the market equation. Lower annual expenses mean VIZZ does not need to grow as quickly to extend runway, while continued prescription acceleration would make every incremental sales dollar more valuable under a leaner cost structure.
Can consumer marketing and telehealth compensate for such a large workforce reduction?
LENZ is betting that presbyopia behaves partly like a consumer-driven healthcare category. Patients experience age-related difficulty focusing on near objects and may actively seek alternatives to reading glasses, creating a market in which consumer awareness can influence treatment demand directly.
The telehealth results offer early support for that thesis. More than half of incremental Q3 prescriptions came through the new channel, indicating that simplifying access can produce measurable growth.
The company is also running national television and targeted digital campaigns. A smaller organisation can work if these channels generate prescriptions more efficiently than maintaining a large sales and administrative infrastructure.
The next several quarters should reveal customer-acquisition economics more clearly. Product sales need to grow much faster than marketing expenditure if LENZ is to demonstrate that the new organisation can eventually reach commercial sustainability.
What are the key takeaways from LENZ Therapeutics’ 75% workforce reduction?
- LENZ Therapeutics is reducing headcount by approximately 75%.
- The post-restructuring organisation is expected to have around 40 full-time employees.
- The company expects approximately $5 million of one-time restructuring charges.
- Projected 2027 operating expenses are being reduced by more than 50% to approximately $70 million to $75 million.
- VIZZ Q3 product sales increased approximately 50% sequentially to $2.6 million.
- Paid prescriptions increased approximately 51% to more than 38,000.
- LENZ held $197.3 million of cash, equivalents and marketable securities at September 30.
- Eef Schimmelpennink will step down as CEO on December 1.
- CFO Dan Chevallard will become interim President and CEO.
- LENZ shares closed at $3.05 on October 30, around 90% below their 52-week high, leaving prescription growth and spending discipline as the main proof points.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
